Modifi Bio co-founders (from L-R): Kingson Lin, Kevin Rakin, Seth Herzon and Ranjit Bindra

October 23, 2024 07:05 AM EDT

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Lei Lei Wu

News Reporter

Merck is acquiring a startup spun out of Yale called Modifi Bio, which has developed a suite of molecules against chemotherapy-resistant glioblastoma, a devastating and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Roche says it is undeterred by upcoming biosimilar threat to Vabysmo

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Mer­ck pays $30M to buy ‘chameleon’ ap­proach to dead­ly brain can­cers

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers